Epitranscriptomic circuits wiring the tumor microenvironment: A pharmacodynamic framework for clinical translation

Epitranscriptomic RNA marks have moved from molecular footnotes to a control layer deciding which transcripts are translated, stored or discarded. In solid tumors, this layer sits directly upstream of how the tumor microenvironment behaves: it links oncogenic signaling to antigen visibility, interferon tone, myeloid recruitment, stromal architecture and vascular fitness through three recurrent "conduit circuits" centered on NF-κB-driven inflammation, Wnt/β-catenin-mediated immune exclusion and Dll4-NOTCH-patterned angiogenesis. Yet translation into clinical practice has lagged: mechanistic work is fragmented, pharmacodynamic rules for short lead-in windows and axis-aligned combinations are rarely shared, and assays range from semi-quantitative bulk measures to non-standardized spatial maps. This review brings mechanistic and clinical observations together into a single map of how epitranscriptomic circuits can be used in trials. It describes how m⁶A and related marks shape these conduit circuits and clinical programs spanning stemness, perivascular niches, angiogenesis, metastasis and treatment resistance, and links them to a bench-to-bedside pharmacodynamic workflow that combines LC-MS, direct RNA sequencing, spatial profiling, perfusion imaging and tumor-informed ctDNA. Finally, four practical operating principles for clinical use of this biology are outlined: pharmacodynamic-gated axis alignment, perfusion-gated vascular normalization, lineage-aware spatial pharmacodynamics and reader-level, compartment-selective control, together with a proposed conduit-circuit response score to judge and combine epitranscriptomic interventions on the basis of tissue-level pharmacodynamic readouts.